Schrodinger Inc Ordinary Shares SDGR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
-
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
-
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
-
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Schrödinger Reports Second Quarter 2026 Financial Results
-
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
Trading Information
- Previous Close Price
- $31.05
- Day Range
- $30.01–31.93
- 52-Week Range
- $10.95–32.45
- Bid/Ask
- $30.48 / $30.89
- Shares Outstanding
- 74.81M
- Market Cap
- $2.28B
- Volume/Avg
- 5M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Core
- Total Number of Employees
- 850
- Website
- https://www.schrodinger.com
Valuation
|
Metric
|
SDGR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.92 |
Price/Sales | 8.70 |
Price/Cash Flow | — |
Price/Earnings
SDGR
Financial Strength
|
Metric
|
SDGR
|
|---|---|
Quick Ratio | 2.62 |
Current Ratio | 2.71 |
Interest Coverage | — |
Quick Ratio
SDGR
Profitability
|
Metric
|
SDGR
|
|---|---|
Return on Assets (Normalized) | −14.08% |
Return on Equity (Normalized) | −28.18% |
Return on Invested Capital (Normalized) | −21.20% |
Return on Assets
SDGR
Health Information Services Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Veeva Systems Inc Class A
VEEV
| LOCK|mNMy#QS | LOCK|#? | $46B | |||
| Tempus AI Inc Class A common stock
TEM
| — | LOCK|C^t | $14B | |||
| Pro Medicus Ltd
PMCUF
| — | LOCK|><z^ | $12B | |||
| Pro Medicus Ltd ADR
PMDIY
| — | LOCK|py>!q | $12B | |||
| BrightSpring Health Services Inc
BTSG
| — | LOCK|M%X@C | $11B | |||
| Hinge Health Inc Ordinary Shares - Class A
HNGE
| — | LOCK|lt#hv | $8B | |||
| M3 Inc
MTHRF
| — | LOCK|RxcVK | $8B | |||
| M3 Inc ADR
MTHRY
| — | LOCK|zB?#d | $8B | |||
| HealthEquity Inc
HQY
| — | LOCK|M#Wqm | $7B | |||
| Doximity Inc Class A
DOCS
| — | LOCK|h@ | $5B |
United States